Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Twitter
  • LinkedIn
  • Instagram
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    Learn How to Conduct Mock Code Simulations
    Clinical practice
    Learn How to Conduct Mock Code Simulations
    August 18, 2023
    Nurse-Led QI Project Standardizes Transplant and Cellular Therapy Nurse Coordinator Visit Scheduling
    Quality of care
    Nurse Practitioner's QI Project Standardizes Transplant and Cellular Therapy Nurse Coordinator Visit Scheduling
    August 03, 2023
    Nurse-Created Apps Help Pediatric Patients Find Their Voice and Navigate Their Cancer Journey
    Patient Support
    Nurse-Created Apps Help Pediatric Patients Find Their Voice and Navigate Their Cancer Journey
    July 21, 2023
    Certification Was a Critical Step Along My Oncology Nursing Career Journey
    Oncology nursing community
    Certification Was a Critical Step Along My Oncology Nursing Career Journey
    July 14, 2023
    Learn How to Read a Germline Genomic Testing Report
    Genetics & genomics
    Learn How to Read a Germline Genomic Testing Report
    July 07, 2023
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan

    After clinical trial results demonstrated a four-month improvement in overall survival compared to best standard care, in March 2022 the U.S. Food and Drug Administration approved lutetium lu 177 vipivotide tetraxetan (PluvictoTM) to treat prostate-specific membrane antigen–expressing metastatic castration-resistant prostate cancer.

    July 26, 2022
    Don’t Ask Patients About Their Symptoms—Have Them Tell You
    Symptom management

    Don’t Ask Patients About Their Symptoms—Have Them Tell You

    “How are you doing?” We ask this question of our patients repeatedly: at diagnosis, during treatment, throughout survivorship, and at end of life. However, studies show that patients often give inaccurate answers to that direct question.

    May 12, 2022
    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tisotumab Vedotin-Tftv

    In clinical trials, 24% of patients achieved an objective response rate with tisotumab vedotin-tftv (TivdakTM) that lasted a median of 8.3 months, leading to the agent’s U.S. Food and Drug Administration September 2021 approval for use in adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

    February 22, 2022
    Nursing Considerations for Bladder Cancer Survivorship Care
    Survivorship care plans

    Nursing Considerations for Bladder Cancer Survivorship Care

    Bladder cancer is the sixth most common cancer in the United States, with an estimated 83,730 adult diagnoses in 2021. Smoking is the greatest risk factor (47% of all cases occur in smokers), followed by advancing age and sex (assigned males are four times more likely to develop bladder cancer than those assigned female). The incidence rate in White people is double that of Black people, but Black people are twice as likely to die from the disease.

    October 07, 2021

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Anne M. Ireland DNP, RN, AOCN®, CENP
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Twitter
  • LinkedIn
  • Instagram
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲